Concentra Group Holdings Parent vs U S Physical Therapy
CON and USPH side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CON and USPH compare
Concentra Group Holdings Parent is the larger company, worth 4.0 times as much as U S Physical Therapy ($5.1B against $1.3B).
Concentra Group Holdings Parent grew revenue faster over the last twelve months (14.0% versus 11.3% for U S Physical Therapy).
Concentra Group Holdings Parent keeps more of each dollar of sales as profit, with a net margin of 8.7% compared with 4.0% at U S Physical Therapy.
Both pay dividends: Concentra Group Holdings Parent yields 0.62% and U S Physical Therapy 2.1%.
Concentra Group Holdings Parent scores higher on the StockData Score (11 against 10 for U S Physical Therapy), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CON | USPH |
|---|---|---|
| Size and price | ||
| Market cap | $5.1B | $1.3B |
| Share price | $40.38 | $85.83 |
| Change, 1 year | 101% | −2.6% |
| Change, 5 years | – | −21.2% |
| Beta (5Y) | 0.54 | 0.76 |
| Employees | 13K | 7,294 |
| StockData Score | ||
| Total score | 11 (better) | 10 |
| Valuation score | 0 | 2 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 3 | 3 |
| Health score | 2 | 2 |
| Dividend score | 3 (better) | 1 |
| Valuation | ||
| P/E | 26.2× | – |
| P/S | 2.3× | 1.6× (better) |
| P/B | 10.8× | 2.9× (better) |
| EV/EBITDA | 14.5× (better) | 15.0× |
| P/FCF | 19.3× (better) | 20.0× |
| FCF yield | 5.2% (better) | 5.0% |
| Fair value | $32.95 | $80.34 |
| Margin of safety | −22.5% | −6.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 14.0% (better) | 11.3% |
| Revenue growth, 5Y average | – | 13.0% |
| Net income growth (TTM) | 33.1% (better) | −15.6% |
| EPS growth (TTM) | 29.4% | – |
| EPS growth, 5Y average | – | −10.6% |
| Profitability | ||
| Gross margin | 29.3% (better) | 18.7% |
| Operating margin | 16.4% (better) | 9.4% |
| Net margin | 8.7% (better) | 4.0% |
| FCF margin | 11.7% (better) | 7.9% |
| Return on equity | 48.5% (better) | 6.8% |
| Return on invested capital | 15.1% (better) | 8.9% |
| Financial health | ||
| Debt / equity | 3.30 | 0.49 (better) |
| Net debt / EBITDA | 3.11 | 1.99 (better) |
| Current ratio | 1.38 (better) | 1.27 |
| Altman Z-score | 2.57 | 2.71 (better) |
| Piotroski F-score | 6 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 0.62% | 2.1% (better) |
| Payout ratio | 16.1% | – |
| Years of dividend growth | 1 | 5 (better) |
| Dividend growth, 5Y average | – | 41.3% |
| Shareholder yield | 0.62% | 2.1% (better) |
| Ownership | ||
| Held by institutions | 88.2% | 109% |
| Held by insiders | 10.8% | 2.6% |
| Insider net buying, 12 months | −$14.6M | −$173K (better) |
| Short interest, % of float | 3.2% | 8.9% |
Go deeper
- CON stock overview
- CON income statement
- CON valuation and score
- USPH stock overview
- USPH income statement
- USPH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.